With colorectal cancer (MRC) being the second biggest cancer type in Hong Kong, it is positive news that Hutchmed has received marketing approval for its Elunate (fruquintinib) small molecule treatment.
Adults and children in the US with congenital thrombotic thrombocytopenic purpura (cTTP) can now access Adzynma for prophylactic and on-demand treatment.
The first and only enzyme replacement therapy for the treatment of a very rare and complex blood disorder has been approved by the US Food and Drug Administration.
A small molecule, oral targeted therapy for adults with metastatic colorectal cancer (CRC) has been approved by the US Food and Drug Administration (FDA).
Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.
Positive phase 3 results from a trial studying fruquintinib, in patients with previously treated colorectal cancer (CRC) were announced by Hutchmed and Takeda on Friday (June 16).
A drug that has the ability to ‘transform the landscape’ for people living with metastatic colorectal cancer (CRC) has been granted priority review by the US Food and Drug Administration (FDA).
Adding to broader action being taken across the industry, the company has signed an agreement with Enel for the supply of renewable energy credits covering its electricity needs across the US.
The pharmaceutical company has forged a partnership with the life-sciences tech firm in an effort to elevate data collection and speed up clinical studies.
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
The pharmaceutical firm and university have launched T-REX, a multi-year partnership focused on increasing health outcomes for underrepresented populations.
The 2022 edition of the Highly Potent Active Pharmaceutical Ingredients Summit (June 28 to 30 in Boston) will take on a range of topics, including safety.
Alongside the first drug developed by AI entering clinical trials, there have been a number of other instances of the technology being used to aid the discovery of new treatments.
Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.
Takeda and Sosei both have a proud heritage in Japan and recently entered a billion-dollar partnership with Sosei to discover, develop, and commercialize molecules for patients in need around the world.
Amgen and Takeda will join fellow big pharma companies Sanofi, GSK, and Janssen, in working to progress Feldan’s intracellular drug delivery technology.
Takeda will become the latest company to base its operations within Massachusetts, after announcing it would leave its Deerfield, Illinois headquarters.
Takeda says it will help Nihon Pharmaceuticals bring manufacturing operations up to code after Japanese regulators order the CMO to halt production and recall one lot of its vitamin B1 shot.
Takeda Pharmaceuticals has joined the growing list of pharma companies to forge strategic deals with contract research organisations (CRO) by signing new deals with Covance and Quintiles.
PPD says it is unlikely to receive a $25m (€20m) milestone for US approval of Takeda’s diabetes drug alogliptin this year after the FDA said that cardio vascular (CV) safety data filed as part of the NDA are insufficient.
Japanese pharma firm Takeda beat off strong competition from the
likes of Coca-Cola to take home the dubious honour of Consumer
International's 'Worst Product' award thanks to its sleeping pill
ad.
PPD managed a net revenue of $313.1m (€250m) for the third quarter
of 2006, an increase of 14.6 per cent over net revenue of $273.3m
for the third quarter of 2005. This has been buoyed on by the
strong performance by the company's...
Japan's Takeda is to invest Y15.0 billion (€117m) in its plant at
Hikari City, in anticipation of the closure of its Shonan facility
in at the end of March 2006.
